Related Experiment Video
Updated: Jul 6, 2026

Isolation and Purification of Fungal β-Glucan as an Immunotherapy Strategy for Glioblastoma
Published on: June 2, 2023
Ginseng Polysaccharides Inhibit Aspergillus sydowii-Driven Lung Adenocarcinoma via Modulating Gut Microbiota-Bile
Jinlian He1, Xiao Shu2, Hudan Pan2
1Guangzhou National Laboratory, Guangzhou 510000, China.
Background:
Lung cancer is the leading cause of cancer-related mortality globally, with lung adenocarcinoma (LUAD) as the most common subtype. Dysbiotic intratumoral mycobiomes drive LUAD pathogenesis, and Aspergillus sydowii (A. sydowii) acts as a key oncogenic fungal species. Ginseng polysaccharides (GPs), bioactive phytochemicals with immunomodulatory and oncostatic properties, counteract fungal infections and restore immunosurveillance in LUAD.
Methods:
Subcutaneous and orthotopic LUAD murine models were established by implanting Lewis lung carcinoma (LLC) cells. Subcutaneous tumors were infected intratumorally and orthotopic models via nasal inoculation. GPs (200 mg/kg/day) were orally administered to evaluate tumor growth. Metagenomic and targeted bile acid metabolomic profiling of fecal and tumor tissues was performed, with Spearman correlations analyzed using R packages.
Results:
GPs significantly inhibited A. sydowii-induced tumor growth in both models. In subcutaneous tumors; GPs reduced volume (p < 0.05) and weight vs. infected controls. In orthotopic models, GPs decreased pathological nodules and lung weight, with micro-CT/H&E confirming attenuated hyperplasia. Metagenomics showed GPs restored gut homeostasis by enriching Lactobacillus/Muribaculum intestinale and suppressing pro-inflammatory Alistipes. Targeted metabolomics revealed reduced β-Hyodeoxycholic Acid (3β-HDCA), Chenodeoxycholic acid 24-acyl-b-D-glucuronide (CDCA-24G) and 3β-hydroxychol-5-en-24-oic acid (5-isoLCA) after GP treatment. Network analysis confirmed significant microbe-bile acid interactions.
Conclusions:
GPs exert antitumor effects against A. sydowii-induced LUAD by modulating gut microbiota and bile acid metabolism. This identifies GPs as a promising therapy for mycobiome-influenced cancers, with dual targeting of fungal infection and metabolic reprogramming.
Insights
Ginseng polysaccharides (GPs) combat Aspergillus sydowii-driven lung cancer by restoring gut bacteria and altering bile acids. This research highlights GPs as a potential therapy for fungal-related cancers.
Area of Science:
- Oncology
- Microbiology
- Pharmacology
Background:
- Lung adenocarcinoma (LUAD) is a leading global cancer killer, often driven by the oncogenic fungus Aspergillus sydowii (A. sydowii).
- Intratumoral mycobiomes contribute to LUAD pathogenesis.
- Ginseng polysaccharides (GPs) possess immunomodulatory and oncostatic properties, showing potential against fungal infections in LUAD.
Purpose of the Study:
- To investigate the antitumor effects of Ginseng polysaccharides (GPs) against Aspergillus sydowii-induced lung adenocarcinoma (LUAD).
- To explore the impact of GPs on gut microbiota and bile acid metabolism in LUAD models.
Main Methods:
- Established subcutaneous and orthotopic LUAD murine models using Lewis lung carcinoma (LLC) cells.
- Administered GPs (200 mg/kg/day) orally and infected models with A. sydowii.
- Performed metagenomic and bile acid metabolomic profiling, analyzing Spearman correlations.
Main Results:
- GPs significantly inhibited A. sydowii-induced tumor growth, reducing volume and weight in subcutaneous models and pathological nodules in orthotopic models.
- Metagenomics revealed GPs restored gut homeostasis by increasing beneficial Lactobacillus/Muribaculum intestinale and decreasing pro-inflammatory Alistipes.
- Metabolomics showed GPs reduced specific bile acids (3β-HDCA, CDCA-24G, 5-isoLCA), with network analysis confirming microbe-bile acid interactions.
Conclusions:
- Ginseng polysaccharides demonstrate antitumor efficacy against A. sydowii-induced LUAD.
- GPs modulate gut microbiota and bile acid metabolism to achieve these effects.
- GPs represent a promising therapeutic strategy for mycobiome-influenced cancers, targeting both fungal infection and metabolic reprogramming.
More Related Videos
Related Concept Videos
Dysbiosis of the Gut Microbiota
Microbiota Modulation by Antibiotics

